A phase II study of 17 RET fusion-positive NSCLC patients previously treated with chemotherapy received vandetanib, targeting VEGFR 2 and 3, EGFR, and RET, and the trial demonstrated a 53% ORR, a median PFS of 4.7 months, and a median OS of 11.1 months [85]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.